

Varicella Zoster (HHV-3) Infections - Pipeline Insight, 2020

<https://marketpublishers.com/r/V67CBF5531AEN.html>

Date: November 2020

Pages: 50

Price: US\$ 1,500.00 (Single User License)

ID: V67CBF5531AEN

Abstracts

This report can be delivered to the clients within 24-48 Hours

DelveInsight's, "Varicella Zoster Infections– Pipeline Insight, 2020," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Varicella Zoster Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Varicella Zoster Infections Understanding

Varicella Zoster Infections: Overview

Varicella-zoster virus (VZV) is a pathogenic human alpha-herpesvirus that causes chickenpox (varicella) as a primary infection, which usually occurs in children in locales where vaccination is not practiced. Following the primary infection, this neurotropic virus becomes latent, primarily in neurons in peripheral autonomic ganglia throughout the entire neuroaxis including dorsal root ganglia (DRG), cranial nerve ganglia such as the trigeminal ganglia (TG), and autonomic ganglia including those in the enteric nervous system.

Symptoms

The symptoms of Varicella-zoster Infections include:

Vesicular pruritic rash mainly on the trunk, head, and face

Extremities are spared

Malaise

Fever

Fatigue

Diagnosis

The diagnosis of VZV infection is usually made clinically by the appearance of the skin rash. In confusing or unusual appearing cases, the diagnosis may be made by identifying VZV DNA in skin lesions by PCR. Culture of VZV from skin lesions may also be used, but it is more expensive, takes more time, is poorly available, and is less sensitive than PCR.

Treatment

Severe varicella may be prevented to some extent by administration of passive immunization with VariZig, a form of immunoglobulin containing high titers of antibodies to VZV; passive immunization should be administered as soon as possible after a recognised close exposure to VZV in a high-risk person who has never had varicella. Patients who develop zoster should be treated as soon as possible with acyclovir, famciclovir, or valacyclovir, which are administered orally. If zoster is severe, especially in immunocompromised patients, intravenous acyclovir can be administered, especially at the start of treatment surgery. Foscarnet is used to treat VZV infections that are resistant to ACV; the drug inhibits synthesis of VZV DNA polymerase.

Varicella-zoster Infections Emerging Drugs Chapters

This segment of the Varicella-zoster Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical

and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Varicella-zoster Infections Emerging Drugs

NBP608: SK Bioscience

NBP608 is an immunostimulant which is being developed by SK Bioscience.

Further product details are provided in the report.....

Varicella-zoster Infections: Therapeutic Assessment

This segment of the report provides insights about the different Varicella-zoster Infections drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Varicella-zoster Infections There are approx. 3+ key companies which are developing the therapies for Varicella-zoster Infections. The companies which have their Varicella-zoster Infections drug candidates in the most advanced stage, i.e. phase III include, SK Bioscience.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Varicella-zoster Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Varicella-zoster Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Varicella-zoster Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Varicella-zoster Infections drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Varicella-zoster Infections R&D. The therapies under development are focused on novel approaches to treat/improve Varicella-zoster Infections.

In May 2020, AbbVie announced that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.

Varicella-zoster Infections Report Insights

Varicella-zoster Infections Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Varicella-zoster Infections Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Varicella-zoster Infections drugs?

How many Varicella-zoster Infections drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Varicella-zoster Infections?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Varicella-zoster Infections therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Varicella-zoster Infections and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Curevo Vaccine

GeneOne Life Science

SK Bioscience

Key Products

NBP608

CRV101

GLS5100

Contents

Introduction

Executive Summary

Varicella-zoster Infections: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Varicella-zoster Infections – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Varicella-zoster Infections companies' collaborations, Licensing, Acquisition -Deal

Value Trends

Varicella-zoster Infections Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

NBP608: SK Bioscience

Product Description

Research and Development

Product Development Activities

Mid Stage Products (Phase II)

Comparative Analysis

Metopimazine: Neurogastrx

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

CRV101: Curevo Vaccine

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

GLS5100: GeneOne Life Science

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Varicella-zoster Infections Key Companies**Varicella-zoster Infections Key Products****Varicella-zoster Infections - Unmet Needs****Varicella-zoster Infections - Market Drivers and Barriers****Varicella-zoster Infections - Future Perspectives and Conclusion****Varicella-zoster Infections Analyst Views****Varicella-zoster Infections Key Companies****Appendix**

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Varicella Zoster Infections
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Varicella Zoster Infections
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Varicella Zoster (HHV-3) Infections - Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/V67CBF5531AEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V67CBF5531AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970